TrialThe Lancet. Oncology2021

Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.

Robert D Morgan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.